Brady Huggett is features editor at The Transmitter, where he writes and edits features and long-form projects. He is also the creator and host of the “Synaptic” podcast. Before joining The Transmitter in 2022, he served as business editor at Nature Biotechnology, and prior to that was the managing editor of BioWorld.
Brady Huggett
Features editor
The Transmitter
From this contributor
Releasing the Hydra with Rafael Yuste
By
Brady Huggett, Shaena Montanari
4 April 2025 | 10 min read
Timothy Ryan on his pivotal switch from studying particle physics to decoding synaptic transmission
By
Brady Huggett
1 October 2024 | 70 min listen
Biosensors and being fearless with Lin Tian
By
Brady Huggett
1 September 2024 | 62 min listen
Education
- M.A. in creative writing, The New School
- M.A. in journalism, University of North Carolina at Chapel Hill
- B.S. in biology from Wake Forest University in Winston-Salem, North Carolina
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
By
Lauren Schneider
4 February 2026 | 7 min read
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
By
Claudia López Lloreda
3 February 2026 | 4 min read
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
By
Calli McMurray
3 February 2026 | 5 min read